Suchergebnisse

Medical Research Council UK (MRC) ; Wellcome Trust 102215/2/13/2 WT088806 084762MA ; Biotechnology and Biological Sciences Research Council (BBSRC) BB/I025751/1 BB/I025263/1 ; UK Medical Research Council Integrative Epidemiology Unit ; University of Bristol MC_UU_12013_1 MC_UU_12013_2 MC_UU_12013_5 MC_UU_12013_8 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) R01 DK10324 ; Swedish Research Council ; Swedish Heart-Lung Foundation ; Freemason Child House Foundation in Stockholm ; European Union (EU) 261357 ; Stockholm County Council ; Swedish Foundation for Strategic Research RBc08-0027 ; Strategic Research Programme (SFO) in Epidemiology at Karolinska Institutet ; Swedish Research Council Swedish Research Council Formas ; Swedish Environment Protection Agency ; Center for Integrative Research on Childhood Leukemia and the Environment P01ES018172 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA P50ES018172 R01ES09137 5P30CA082103 P01 ES009605 R01 ES021369 R01ES023067 K01ES017801 R01ES022216 P30ES007048 R01ES014447 P01ES009581 R826708-01 RD831861-01 P50ES026086 R01DK068001 R01 DK100340 R01 DK076648 R01ES022934 R01HL111108 R01NR013945 R37 HD034568 UL1 TR001082 P30 DK56350 ; United States Environmental Protection Agency RD83451101 RD83615901 RD 82670901 RD 83451301 83615801-0 ; UCSF Comprehensive Cancer Center Support grant P30 CA82103 ; Swiss National Science Foundation (SNSF) P2LAP3_158674 ; Sutter-Stottner Foundation ; European Union (EU) QLRT-2001-00389 QLK1-CT-2002-30582 ; European Union (EU) 007036 ; European Union (EU) 289346 ; European Research Council (ERC) 322605 META-GROWTH ; European Research Council (ERC) 322605 META-GROWTH ; Funds for Research in Respiratory Health ; Ministry of Research, France ; Institut National de la Sante et de la Recherche Medicale (Inserm) ; French Ministry of Health: Perinatality Program ; French National Institute for Population Health Surveillance (INVS) ; Paris-Sud University ; Institut National de la Sante et de la Recherche Medicale (Inserm) ; Nestle ; Mutuelle Generale de l'Education Nationale (MGEN) ; French-speaking association for the study of diabetes and metabolism (Alfediam) 2012/51290-6 ; European Research Council (ERC) ERC-2012-StG.310898 268479-BREATHE ; Flemish Scientific Research Council (FWO) N1516112 / G.0.873.11N.10 ; European Community's Seventh Framework Programme FP7 project EXPOsOMICS 308610 ; European Union (EU) 628858 ; Bijzonder Onderzoeksfonds (BOF) Hasselt University ; Ministry of the Flemish Community (Department of Economics, Science and Innovation) ; Ministry of the Flemish Community (Department of Environment, Nature and Energy) ; FWO ; FWO 12L5216N ; Flemish Institute for Technological Research (VITO) 12L5216N ; Bill AMP; Melinda Gates Foundation Grand Challenges Exploration grant OPP119403 ; Sandler Family Foundation ; American Asthma Foundation ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Heart Lung & Blood Institute (NHLBI) HL117004 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Environmental Health Sciences (NIEHS) ES24844 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute on Minority Health & Health Disparities (NIMHD) MD006902 MD00952 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of General Medical Sciences (NIGMS) GM007546 ; University of California System 24RT-0025 ; Hutchison Whampoa Ltd, Hong Kong ; University of Groningen ; Well Baby Clinic Foundation Icare ; Noordlease ; Youth Health Care Drenthe ; Biobanking and Biomolecular Research Infrastructure Netherlands CP2011-19 ; Erasmus Medical Center, Rotterdam ; Erasmus University Rotterdam ; Netherlands Organization for Health Research and Development ; Netherlands Organization for Scientific Research (NWO) ; Netherlands Consortium for Healthy Aging (NCHA) 050-060-810 ; Genetic Laboratory of the Department of Internal Medicine, Erasmus MC ; European Union's Horizon research and innovation programme 733206 633595 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) R01HD068437 ; Netherlands Organization for Health Research and Development VIDI 016.136.361 ; Consolidator grant from the European Research Council ERC-2014-CoG-648916 ; Netherlands Organization for Scientific Research (NWO) ; European Research Council (ERC) ; Netherlands' Organization for Scientific Research (NWO Spinoza Award) ; Gravitation program of the Dutch Ministry of Education, Culture, and Science ; Netherlands Organization for Scientific Research (NWO) 024.001.003 ; Lung Foundation Netherlands 3.2.12.089 ; Fonds de Recherche du Quebec en Sante (FRQ-S) 2069 ; Canadian Institutes of Health Research (CIHR) MOP 115071 ; Diabete Quebec grant ; Canadian Diabetes Association operating grant OG-3-08-2622 ; American Diabetes Association 1-15-ACE-26 ; Medical Research Council UK (MRC) MC_UU_12013/1-9 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Environmental Health Sciences (NIEHS) K99ES025817 ; Instituto de Salud Carlos III Red INMA G03/176 CB06/02/0041 ; Instituto de Salud Carlos III Spanish Government FIS-PI04/1436 FIS-PI08/1151 ; Spanish Ministry of Health (FEDER funds) FIS-PI11/00610 FIS-FEDER-PI06/0867 FIS-FEDER-PI03-1615 ; Generalitat de Catalunya CIRIT 1999SGR 00241 ; Fundacio La Marato de TV3 090430 ; European Commission European Commission Joint Research Centre 261357-MeDALL ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Allergy & Infectious Diseases (NIAID) N01-AI90052 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA R01 HL082925 R01 HL132321 ; Asthma UK 364 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Allergy & Infectious Diseases (NIAID) R01AI091905 R01AI121226 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA R01AI121226 R01 AI091905 R01HL132321 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Environmental Health Sciences (NIEHS) N01-ES75558 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Neurological Disorders & Stroke (NINDS) 1 UO1 NS 047537-01 2 UO1 NS 047537-06A1 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Environmental Health Sciences (NIEHS) Z01-ES-49019 Z01 ES044005 ES049033 ES049032 ; Norwegian Research Council/BIOBANK 221097 ; Oslo University Hospital ; Unger-Vetlesens foundation ; Norwegian American Womens Club ; INCA/Plan Cancer-EVA-INSERM, France ; International Childhood Cancer Cohort Consortium (I4C) ; INCA/Plan Cancer-EVA-INSERM (France) ; IARC Postdoctoral Fellowship ; EC FP7 Marie Curie Actions-People-Co-funding of regional, national and international programmes (COFUND) ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Environmental Health Sciences (NIEHS) R21ES014947 R01ES016772 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) R01DK085173 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Environmental Health Sciences (NIEHS) P30 ES025128 ; University of Oulu grant 65354 ; Oulu University Hospital 2/97 8/97 ; Ministry of Health and Social Affairs 23/251/97 160/97 190/97 ; National Institute for Health and Welfare, Helsinki 54121 ; Regional Institute of Occupational Health, Oulu, Finland 50621 54231 ; European Union (EU) QLG1-CT-2000-01643 E51560 ; NorFA grant 731 20056 30167 ; Academy of Finland ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Environmental Health Sciences (NIEHS) P01 ES022832 ; United States Environmental Protection Agency RD83544201 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of General Medical Sciences (NIGMS) P20GM104416 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI) R25CA134286 ; Netherlands Organization for Scientific Research and Development ; Netherlands Asthma Fund ; Netherlands Ministry of Spatial Planning, Housing, and the Environmen ; Netherlands Ministry of Health, Welfare, and Sport ; MeDALL ; European Union (EU) 261357v ; Italian National Centre for Disease Prevention and Control (CCM grant) ; Italian Ministry of Health (art 12) ; Italian Ministry of Health (12bis Dl.gs.vo) 502/92 ; Italian Ministry of Health (12bis Dl.gs.vo) 502/92 ; EraNet ; EVO ; University of Helsinki Research Funds ; Signe and Ane Gyllenberg foundation ; Emil Aaltonen Foundation ; Finnish Medical Foundation ; Jane and Aatos Erkko Foundation ; Novo Nordisk Foundation ; Paivikki and Sakari Sohlberg Foundation ; Sigrid Juselius Foundation ; University of Helsinki ; University of Western Australia (UWA) ; Curtin University ; Raine Medical Research Foundation ; UWA Faculty of Medicine, Dentistry and Health Sciences ; Fondazione Telethon ; Women's and Infant's Research Foundation (KEMH) ; Edith Cowan University ; National Health and Medical Research Council of Australia 1059711 ; National Health and Medical Research Council of Australia 1053384 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA ; Greek Ministry of Health (programme of prevention of obesity and neurodevelopmental disorders in preschool children, in Heraklion district, Crete, Greece) ; Greek Ministry of Health ('Rhea Plus': Primary Prevention Program of Environmental Risk Factors for Reproductive Health, and Child Health) ; European Union (EU) EU FP6-2003-Food-3-NewGeneris EU FP7 ENV.2007.1.2.2.2 211250 ESCAPE EU FP7-2008-ENV-1.2.1.4 Envirogenomarkers EU FP7 ENV.2008.1.2.1.6 226285 ENRIECO ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH-NIMH R01MH094609 NIH-NIEHS R01ES022223 NIH-NIEHS R01ES025145 ; United States Department of Health & Human Services Centers for Disease Control & Prevention - USA U10DD000180 U10DD000181 U10DD000182 U10DD000183 U10DD000184 U10DD000498 ; Autism Speaks 7659 ; Swedish Research Council through the Swedish Initiative for research on Microdata in the Social And Medical Sciences (SIMSAM) 340-2013-5867 ; Stockholm County Council ; Strategic Research Program in Epidemiology at Karolinska Institutet ; Swedish Asthma and Allergy Association's Research Foundation ; Stiftelsen Frimurare Barnahuset Stockholm ; Norwegian Ministry of Health and Care Services ; Ministry of the Flemish Community (Flemish Agency for Care and Health) ; University of Bristol ; Ministry of Education and Research ; European Union (EU) ; European Union (EU) 308333 HELIX ; R01ES017646 R01ES01900 R01ES16443 USA / NIHH 2000 G DF682 50945 R01 HL095606 R01 HL1143396 ; Biotechnology and Biological Sciences Research Council (BBSRC) BB/I025263/1 BB/I025751/1 ; Medical Research Council UK (MRC) MC_PC_15018 MC_UU_12013/2 G9815508 MC_UU_12013/1 ; Novo Nordisk Foundation Hansen Group ; United States Department of Health & Human Services Centers for Disease Control & Prevention - USA U10DD000183 U01DD000498 U10DD000182 U10DD000184 U10DD000180 U10DD000181 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI) P30CA082103 R25CA134286 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Center for Advancing Translational Sciences (NCATS) UL1TR001082 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Heart Lung & Blood Institute (NHLBI) R01HL082925 R01HL132321 R01HL095606 R01HL111108 ; nited States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Allergy & Infectious Diseases (NIAID) R01AI091905 R01AI121226 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) R01DK068001 P30DK056350 R01DK076648 R01DK085173 R01DK100340 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Environmental Health Sciences (NIEHS) P30ES007048 P01ES009605 P01ES022832 P50ES018172 R01ES023067 ZIAES049019 P30ES017885 ZIAES044003 P01ES009581 R01ES014447 R00ES023450 R01ES009137 R01ES021369 P01ES018172 P30ES025128 R24ES028507 Z01ES044005 P50ES026086 ZIAES049032 R01ES016443 K99ES025817 R01ES016772 Z01ES049019 R01ES025145 R01ES022216 R01ES022223 ZIAES049027 K01ES017801 R00ES024116 R01ES022934 R01ES029212 R01ES017646 ZIAES049033 R21ES014947 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of General Medical Sciences (NIGMS) P20GM104416 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Mental Health (NIMH) R01MH094609 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Neurological Disorders & Stroke (NINDS) U01NS047537 ; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Nursing Research (NINR) R01NR013945

Background: DNA methylation has been shown to be associated with adiposity in adulthood. However, whether similar DNA methylation patterns are associated with childhood and adolescent body mass index (BMI) is largely unknown. More insight into this relationship at younger ages may have implications for future prevention of obesity and its related traits. Methods: We examined whether DNA methylation in cord blood and whole blood in childhood and adolescence was associated with BMI in the age range from 2 to 18 years using both cross-sectional and longitudinal models. We performed meta-analyses of epigenome-wide association studies including up to 4133 children from 23 studies. We examined the overlap of findings reported in previous studies in children and adults with those in our analyses and calculated enrichment. Results: DNA methylation at three CpGs (cg05937453, cg25212453, and cg10040131), each in a different age range, was associated with BMI at Bonferroni significance, P < 1.06 × 10-7, with a 0.96 standard deviation score (SDS) (standard error (SE) 0.17), 0.32 SDS (SE 0.06), and 0.32 BMI SDS (SE 0.06) higher BMI per 10% increase in methylation, respectively. DNA methylation at nine additional CpGs in the cross-sectional childhood model was associated with BMI at false discovery rate significance. The strength of the associations of DNA methylation at the 187 CpGs previously identified to be associated with adult BMI, increased with advancing age across childhood and adolescence in our analyses. In addition, correlation coefficients between effect estimates for those CpGs in adults and in children and adolescents also increased. Among the top findings for each age range, we observed increasing enrichment for the CpGs that were previously identified in adults (birth Penrichment = 1; childhood Penrichment = 2.00 × 10-4; adolescence Penrichment = 2.10 × 10-7). Conclusions: There were only minimal associations of DNA methylation with childhood and adolescent BMI. With the advancing age of the participants across childhood and adolescence, we observed increasing overlap with altered DNA methylation loci reported in association with adult BMI. These findings may be compatible with the hypothesis that DNA methylation differences are mostly a consequence rather than a cause of obesity. ; The work on this meta-analysis received funding from the European Union's Horizon 2020 research and innovation program (733206, LIFECYCLE; 633595, DynaHEALTH) and from the European Joint Programming Initiative "A Healthy Diet for a Healthy Life" (JPI HDHL, NutriPROGRAM project, ZonMw, the Netherlands, no.529051022). Funding statements for all participating studies can be found in Additional file 2: Supplementary Methods.

Background: Prenatal inflammation has been proposed as an important mediating factor in several adverse pregnancy outcomes. C-reactive protein (CRP) is an inflammatory cytokine easily measured in blood. It has clinical value due to its reliability as a biomarker for systemic inflammation and can indicate cellular injury and disease severity. Elevated levels of CRP in adulthood are associated with alterations in DNA methylation. However, no studies have prospectively investigated the relationship between maternal CRP levels and newborn DNA methylation measured by microarray in cord blood with reasonable epigenome-wide coverage. Importantly, the timing of inflammation exposure during pregnancy may also result in different effects. Thus, our objective was to evaluate this prospective association of CRP levels measured during multiple periods of pregnancy and in cord blood at delivery which was available in one cohort (i.e., Effects of Aspirin in Gestation and Reproduction trial), and also to conduct a meta-analysis with available data at one point in pregnancy from three other cohorts from the Pregnancy And Childhood Epigenetics consortium (PACE). Secondarily, the impact of maternal randomization to low dose aspirin prior to pregnancy on methylation was assessed. Results: Maternal CRP levels were not associated with newborn DNA methylation regardless of gestational age of measurement (i.e., CRP at approximately 8, 20, and 36 weeks among 358 newborns in EAGeR). There also was no association in the meta-analyses (all p > 0.5) with a larger sample size (n = 1603) from all participating PACE cohorts with available CRP data from first trimester (< 18 weeks gestation). Randomization to aspirin was not associated with DNA methylation. On the other hand, newborn CRP levels were significantly associated with DNA methylation in the EAGeR trial, with 33 CpGs identified (FDR corrected p < 0.05) when both CRP and methylation were measured at the same time point in cord blood. The top 7 CpGs most strongly associated with CRP resided in inflammation and vascular-related genes. Conclusions: Maternal CRP levels measured during each trimester were not associated with cord blood DNA methylation. Rather, DNA methylation was associated with CRP levels measured in cord blood, particularly in gene regions predominately associated with angiogenic and inflammatory pathways. ; This work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (National Institutes of Health, Bethesda, MD, USA), and the EAGeR trial was specifically funded under contract numbers HHSN267200603423, HHSN267200603424, HHSN267200603426, and HHSN275201300023I-HHSN2750008. SL was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. Main funding of the epigenetic studies in INMA was grants from Instituto de Salud Carlos III (Red INMA G03/176, CB06/02/0041), Spanish Ministry of Health (FIS-PI04/1436, FIS-PI08/1151 including FEDER funds, FIS-PI11/00610, FIS-FEDER-PI06/0867, FIS-FEDER-PI03-1615, MS13/00054, CP18/00018), Generalitat de Catalunya-CIRIT 1999SGR 00241, Fundació La marató de TV3 (090430), EU Commission (261357-MeDALL: Mechanisms of the Development of ALLergy), and European Research Council (268479-BREATHE: BRain dEvelopment and Air polluTion ultrafine particles in scHool childrEn). The general design of the Generation R Study is made possible by financial support from the Erasmus Medical Center, Rotterdam; the Erasmus University Rotterdam; the Netherlands Organization for Health Research and Development; and the Ministry of Health, Welfare and Sport. The EWAS data was funded by a grant from the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO), Netherlands Consortium for Healthy Aging (NCHA; project nr. 050-060-810), by funds from the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, and by a grant from the National Institute of Child and Human Development (R01HD068437). This project received funding from the European Union's Horizon 2020 research and innovation programme (633595, DynaHEALTH: 733206, LIFECYCLE) and from the European Joint Programming Initiative "A Healthy Diet for a Healthy Life" (JPI HDHL, NutriPROGRAM project, ZonMw the Netherlands no.529051022; and Precise project, ZonMw the Netherlands no. P75416). LD has received funding from the European Joint Programming Initiative. The PREDO study has been funded by the Academy of Finland, EraNet Neuron, EVO (a special state subsidy for health science research), University of Helsinki Research Funds, the Signe and Ane Gyllenberg Foundation, the Emil Aaltonen Foundation, the Finnish Medical Foundation, the Jane and Aatos Erkko Foundation, the Novo Nordisk Foundation, the Päivikki and Sakari Sohlberg Foundation, and the Sigrid Juselius Foundation granted to members of the PREDO study board. Methylation assays were funded by the Academy of Finland.

Introduction Depression, cardiovascular diseases and diabetes are among the major non-communicable diseases, leading to significant disability and mortality worldwide. These diseases may share environmental and genetic determinants associated with multimorbid patterns. Stressful early-life events are among the primary factors associated with the development of mental and physical diseases. However, possible causative mechanisms linking early life stress (ELS) with psycho-cardio-metabolic (PCM) multi-morbidity are not well understood. This prevents a full understanding of causal pathways towards the shared risk of these diseases and the development of coordinated preventive and therapeutic interventions. Methods and analysis This paper describes the study protocol for EarlyCause, a large-scale and inter-disciplinary research project funded by the European Union's Horizon 2020 research and innovation programme. The project takes advantage of human longitudinal birth cohort data, animal studies and cellular models to test the hypothesis of shared mechanisms and molecular pathways by which ELS shapes an individual's physical and mental health in adulthood. The study will research in detail how ELS converts into biological signals embedded simultaneously or sequentially in the brain, the cardiovascular and metabolic systems. The research will mainly focus on four biological processes including possible alterations of the epigenome, neuroendocrine system, inflammatome, and the gut microbiome. Life-course models will integrate the role of modifying factors as sex, socioeconomics, and lifestyle with the goal to better identify groups at risk as well as inform promising strategies to reverse the possible mechanisms and/or reduce the impact of ELS on multi-morbidity development in high-risk individuals. These strategies will help better manage the impact of multi-morbidity on human health and the associated risk.

International audience ; Introduction: Depression, cardiovascular diseases and diabetes are among the major non-communicable diseases, leading to significant disability and mortality worldwide. These diseases may share environmental and genetic determinants associated with multimorbid patterns. Stressful early-life events are among the primary factors associated with the development of mental and physical diseases. However, possible causative mechanisms linking early life stress (ELS) with psycho-cardio-metabolic (PCM) multi-morbidity are not well understood. This prevents a full understanding of causal pathways towards the shared risk of these diseases and the development of coordinated preventive and therapeutic interventions.Methods and analysis: This paper describes the study protocol for EarlyCause, a large-scale and inter-disciplinary research project funded by the European Union's Horizon 2020 research and innovation programme. The project takes advantage of human longitudinal birth cohort data, animal studies and cellular models to test the hypothesis of shared mechanisms and molecular pathways by which ELS shapes an individual's physical and mental health in adulthood. The study will research in detail how ELS converts into biological signals embedded simultaneously or sequentially in the brain, the cardiovascular and metabolic systems. The research will mainly focus on four biological processes including possible alterations of the epigenome, neuroendocrine system, inflammatome, and the gut microbiome. Life-course models will integrate the role of modifying factors as sex, socioeconomics, and lifestyle with the goal to better identify groups at risk as well as inform promising strategies to reverse the possible mechanisms and/or reduce the impact of ELS on multi-morbidity development in high-risk individuals. These strategies will help better manage the impact of multi-morbidity on human health and the associated risk.

International audience ; Introduction: Depression, cardiovascular diseases and diabetes are among the major non-communicable diseases, leading to significant disability and mortality worldwide. These diseases may share environmental and genetic determinants associated with multimorbid patterns. Stressful early-life events are among the primary factors associated with the development of mental and physical diseases. However, possible causative mechanisms linking early life stress (ELS) with psycho-cardio-metabolic (PCM) multi-morbidity are not well understood. This prevents a full understanding of causal pathways towards the shared risk of these diseases and the development of coordinated preventive and therapeutic interventions.Methods and analysis: This paper describes the study protocol for EarlyCause, a large-scale and inter-disciplinary research project funded by the European Union's Horizon 2020 research and innovation programme. The project takes advantage of human longitudinal birth cohort data, animal studies and cellular models to test the hypothesis of shared mechanisms and molecular pathways by which ELS shapes an individual's physical and mental health in adulthood. The study will research in detail how ELS converts into biological signals embedded simultaneously or sequentially in the brain, the cardiovascular and metabolic systems. The research will mainly focus on four biological processes including possible alterations of the epigenome, neuroendocrine system, inflammatome, and the gut microbiome. Life-course models will integrate the role of modifying factors as sex, socioeconomics, and lifestyle with the goal to better identify groups at risk as well as inform promising strategies to reverse the possible mechanisms and/or reduce the impact of ELS on multi-morbidity development in high-risk individuals. These strategies will help better manage the impact of multi-morbidity on human health and the associated risk.

International audience ; Introduction: Depression, cardiovascular diseases and diabetes are among the major non-communicable diseases, leading to significant disability and mortality worldwide. These diseases may share environmental and genetic determinants associated with multimorbid patterns. Stressful early-life events are among the primary factors associated with the development of mental and physical diseases. However, possible causative mechanisms linking early life stress (ELS) with psycho-cardio-metabolic (PCM) multi-morbidity are not well understood. This prevents a full understanding of causal pathways towards the shared risk of these diseases and the development of coordinated preventive and therapeutic interventions.Methods and analysis: This paper describes the study protocol for EarlyCause, a large-scale and inter-disciplinary research project funded by the European Union's Horizon 2020 research and innovation programme. The project takes advantage of human longitudinal birth cohort data, animal studies and cellular models to test the hypothesis of shared mechanisms and molecular pathways by which ELS shapes an individual's physical and mental health in adulthood. The study will research in detail how ELS converts into biological signals embedded simultaneously or sequentially in the brain, the cardiovascular and metabolic systems. The research will mainly focus on four biological processes including possible alterations of the epigenome, neuroendocrine system, inflammatome, and the gut microbiome. Life-course models will integrate the role of modifying factors as sex, socioeconomics, and lifestyle with the goal to better identify groups at risk as well as inform promising strategies to reverse the possible mechanisms and/or reduce the impact of ELS on multi-morbidity development in high-risk individuals. These strategies will help better manage the impact of multi-morbidity on human health and the associated risk.

Introduction Depression, cardiovascular diseases and diabetes are among the major non-communicable diseases, leading to significant disability and mortality worldwide. These diseases may share environmental and genetic determinants associated with multimorbid patterns. Stressful early-life events are among the primary factors associated with the development of mental and physical diseases. However, possible causative mechanisms linking early life stress (ELS) with psycho-cardio-metabolic (PCM) multi-morbidity are not well understood. This prevents a full understanding of causal pathways towards the shared risk of these diseases and the development of coordinated preventive and therapeutic interventions. Methods and analysis This paper describes the study protocol for EarlyCause, a large-scale and inter-disciplinary research project funded by the European Union's Horizon 2020 research and innovation programme. The project takes advantage of human longitudinal birth cohort data, animal studies and cellular models to test the hypothesis of shared mechanisms and molecular pathways by which ELS shapes an individual's physical and mental health in adulthood. The study will research in detail how ELS converts into biological signals embedded simultaneously or sequentially in the brain, the cardiovascular and metabolic systems. The research will mainly focus on four biological processes including possible alterations of the epigenome, neuroendocrine system, inflammatome, and the gut microbiome. Life-course models will integrate the role of modifying factors as sex, socioeconomics, and lifestyle with the goal to better identify groups at risk as well as inform promising strategies to reverse the possible mechanisms and/or reduce the impact of ELS on multi-morbidity development in high-risk individuals. These strategies will help better manage the impact of multi-morbidity on human health and the associated risk.

Depression, cardiovascular diseases and diabetes are among the major non-communicable diseases, leading to significant disability and mortality worldwide. These diseases may share environmental and genetic determinants associated with multimorbid patterns. Stressful early-life events are among the primary factors associated with the development of mental and physical diseases. However, possible causative mechanisms linking early life stress (ELS) with psycho-cardio-metabolic (PCM) multi-morbidity are not well understood. This prevents a full understanding of causal pathways towards the shared risk of these diseases and the development of coordinated preventive and therapeutic interventions. ; This work is supported by the European Union's Horizon 2020 research and innovation programme (grant n ̊ 848158). ; Peer reviewed

Introduction: Depression, cardiovascular diseases and diabetes are among the major non-communicable diseases, leading to significant disability and mortality worldwide. These diseases may share environmental and genetic determinants associated with multimorbid patterns. Stressful early-life events are among the primary factors associated with the development of mental and physical diseases. However, possible causative mechanisms linking early life stress (ELS) with psycho-cardio-metabolic (PCM) multi-morbidity are not well understood. This prevents a full understanding of causal pathways towards the shared risk of these diseases and the development of coordinated preventive and therapeutic interventions. Methods and analysis: This paper describes the study protocol for EarlyCause, a large-scale and inter-disciplinary research project funded by the European Union's Horizon 2020 research and innovation programme. The project takes advantage of human longitudinal birth cohort data, animal studies and cellular models to test the hypothesis of shared mechanisms and molecular pathways by which ELS shapes an individual's physical and mental health in adulthood. The study will research in detail how ELS converts into biological signals embedded simultaneously or sequentially in the brain, the cardiovascular and metabolic systems. The research will mainly focus on four biological processes including possible alterations of the epigenome, neuroendocrine system, inflammatome, and the gut microbiome. Life-course models will integrate the role of modifying factors as sex, socioeconomics, and lifestyle with the goal to better identify groups at risk as well as inform promising strategies to reverse the possible mechanisms and/or reduce the impact of ELS on multi-morbidity development in high-risk individuals. These strategies will help better manage the impact of multi-morbidity on human health and the associated risk.

Introduction: Depression, cardiovascular diseases and diabetes are among the major non-communicable diseases, leading to significant disability and mortality worldwide. These diseases may share environmental and genetic determinants associated with multimorbid patterns. Stressful early-life events are among the primary factors associated with the development of mental and physical diseases. However, possible causative mechanisms linking early life stress (ELS) with psycho-cardio-metabolic (PCM) multi-morbidity are not well understood. This prevents a full understanding of causal pathways towards shared risk of these diseases and the development of coordinated preventive and therapeutic interventions. Methods and analysis: This paper describes the study protocol for EarlyCause, a large-scale and inter-disciplinary research project funded by the European Union's Horizon 2020 research and innovation programme. The project takes advantage of human longitudinal birth cohort data, animal studies and cellular models to test the hypothesis of shared mechanisms and molecular pathways by which ELS shape an individual's physical and mental health in adulthood. The study will research in detail how ELS converts into biological signals embedded simultaneously or sequentially in the brain, the cardiovascular and metabolic systems. The research will mainly focus on four biological processes including possible alterations of the epigenome, neuroendocrine system, inflammatome, and the gut microbiome. Life course models will integrate the role of modifying factors as sex, socioeconomics, and lifestyle with the goal to better identify groups at risk as well as inform promising strategies to reverse the possible mechanisms and/or reduce the impact of ELS on multi-morbidity development in high-risk individuals. These strategies will help better manage the impact of multi-morbidity on human health and the associated risk. Ethics and dissemination: The study has been approved by the Ethics Board of the European Commission. The results ...

To access publisher's full text version of this article click on the hyperlink at the bottom of the page ; Reduced glomerular filtration rate defines chronic kidney disease and is associated with cardiovascular and all-cause mortality. We conducted a meta-analysis of genome-wide association studies for estimated glomerular filtration rate (eGFR), combining data across 133,413 individuals with replication in up to 42,166 individuals. We identify 24 new and confirm 29 previously identified loci. Of these 53 loci, 19 associate with eGFR among individuals with diabetes. Using bioinformatics, we show that identified genes at eGFR loci are enriched for expression in kidney tissues and in pathways relevant for kidney development and transmembrane transporter activity, kidney structure, and regulation of glucose metabolism. Chromatin state mapping and DNase I hypersensitivity analyses across adult tissues demonstrate preferential mapping of associated variants to regulatory regions in kidney but not extra-renal tissues. These findings suggest that genetic determinants of eGFR are mediated largely through direct effects within the kidney and highlight important cell types and biological pathways. ; HHSN268201100009C/HL/NHLBI NIH HHS/United States K12 RR023250/RR/NCRR NIH HHS/United States P30 DK072488/DK/NIDDK NIH HHS/United States R01 AG018728/AG/NIA NIH HHS/United States R01 AG033193/AG/NIA NIH HHS/United States R01 DK058845/DK/NIDDK NIH HHS/United States R01 DK066574/DK/NIDDK NIH HHS/United States R01 DK075787/DK/NIDDK NIH HHS/United States R01 DK084350/DK/NIDDK NIH HHS/United States R01 DK089256/DK/NIDDK NIH HHS/United States R01 HL087641/HL/NHLBI NIH HHS/United States R01 HL087660/HL/NHLBI NIH HHS/United States R01 HL088119/HL/NHLBI NIH HHS/United States R01 HL117078/HL/NHLBI NIH HHS/United States R01DK090311/DK/NIDDK NIH HHS/United States R24OD017870/OD/NIH HHS/United States T32 HL007024/HL/NHLBI NIH HHS/United States U01 GM074518/GM/NIGMS NIH HHS/United States U01 HG004399/HG/NHGRI NIH HHS/United States U01 ...

Background: Prenatal exposure to air pollution has been associated with childhood respiratory disease and other adverse outcomes. Epigenetics is a suggested link between exposures and health outcomes. Objectives: We aimed to investigate associations between prenatal exposure to particulate matter (PM) with diameter <10 (PM10) or <2.5 mu m (PM2.5) and DNA methylation in newborns and children. Methods: We meta-analyzed associations between exposure to PM10 (n=1,949) and PM2.5 (n=1,551) at maternal home addresses during pregnancy and newborn DNA methylation assessed by Illumina Infinium HumanMethylation450K BeadChip in nine European and American studies, with replication in 688 independent newborns and look-up analyses in 2,118 older children. We used two approaches, one focusing on single cytosine-phosphate-guanine (CpG) sites and another on differentially methylated regions (DMRs). We also related PM exposures to blood mRNA expression. Results: Six CpGs were significantly associated [false discovery rate (FDR) <0.05] with prenatal PM10 and 14 with PM2.5 exposure. Two of the PM10-related CpGs mapped to FAM13A (cg00905156) and NOTCH4 (cg06849931) previously associated with lung function and asthma. Although these associations did not replicate in the smaller newborn sample, both CpGs were significant (p<0.05) in 7- to 9-y-olds. For cg06849931, however, the direction of the association was inconsistent. Concurrent PM10 exposure was associated with a significantly higher NOTCH4 expression at age 16 y. We also identified several DMRs associated with either prenatal PM10 and or PM2.5 exposure, of which two PM10-related DMRs, including H19 and MARCH11, replicated in newborns. Conclusions: Several differentially methylated CpGs and DMRs associated with prenatal PM exposure were identified in newborns, with annotation to genes previously implicated in lung-related outcomes. ; ALSPAC: The UK Medical Research Council and the Wellcome Trust (Grant ref. 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and P.Y. will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristoLac.uk/alspac/external/documents/grant-acknowledgements.pdf). This research was specifically funded by a joint grant from the UK Economic & Social and Biotechnology & Biological Sciences Research Councils (Grant ref. ES/N000498/1). ALSPAC was funded by the BBSRC (BBI025751/1 and BB/I025263/1). Air pollution exposure assessment was funded by Public Health England as part of the MRC-PHE Centre for Environment and Health, funded also by the UK Medical Research Council (Grant ref. MR/L01341X/1). This paper does not necessarily reflect the views of Public Health England or the Department of Health. BAMSE was supported by The Swedish Research Council, The Swedish Heart-Lung Foundation, Freemason Child House Foundation in Stockholm, MeDALL (Mechanisms of the Development of ALLergy) a collaborative project conducted within the European Union (grant agreement No. 261357), Centre for Allergy Research, Stockholm County Council (ALE), Swedish Foundation for Strategic Research (SSF) (RBc08-0027), the Strategic Research Programme (SFO) in Epidemiology at Karolinska Institutet, The Swedish Research Council Foams, and the Swedish Environment Protection Agency. E.M. is supported by a grant from the European Research Council under the European Union (EU) Horizon 2020 (H2020) research and innovation programme (grant agreement number 757919, TRIBAL). O.G. is supported by Forte (Swedish Research Council for Health, Working Life and Welfare) and The Swedish Society for Medical Research. CHS: This work was supported by NIEHS grants K01ES017801, R01ES022216, and P30ES007048. EARLI: This work was supported by NIH grants R01ES016443, R01ES023780, and R01ES017646 as well as by Autism Speaks (AS 5938). ENVIRONAGE: The ENVIRONAGE birth cohort is funded by the European Research Counsil (ERC-2012-StG.310898) and by funds of the Flemisch Scientific Research Council (FWO, N1516112/G.0.873.11N.10). The methylation assays were funded by the European Community's Seventh Framework Programme FP7/2007-2013 project EXPOsOMICS (grant no. 308610). Z.H. is supported by the Exposomics EC FP7 grant (Grant agreement no. 308610). ZH and A.G. and the Epigenetics Group at IARC are supported by grants from the Institut National du Cancer (INCa, Plan Cancer-EVA-Inserm, France) and Association pour la Recherche sur le Cancer (ARC, France). Generation R Study: The general design of the Generation R Study is made possible by financial support from the Erasmus Medical Center (MC), Rotterdam, the Erasmus University Rotterdam, Netherlands Organization for Health Research and Development and the Ministry of Health, Welfare and Sport. The EWAS data was funded by a grant to VWJ from Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA; project no. 050-060-810), by funds from the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC. V.W.J. also received a grant from Netherlands Organization for Health Research and Development (VIDI 016.136.361) and a Consolidator Grant from the European Research Council (ERC-2014-CoG-648916). J.F.F. has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement no. 633595 (DynaHEALTH). This project received funding from the European Union's Horizon 2020 Research and Innovation Programme (733206, LIFECYCLE). HELIX: The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-206) under grant agreement no 308333 - the HELIX project. R.G. received the grant of the Lithuanian Agency for Science Innovation and Technology (No. 45 31V-66). The Norwegian Mother and Child Cohort Study (MoBa) is supported by the Ministry of Health and Care Services and the Ministry of Education and Research, NIH/NIEHS (contract no. N01-ES-75558), NIH/NINDS (grant no. 1 UO1 NS 047537-01 and grant no. 2 UO1 NS 047537-06A1). INMA: This study was funded by grants from Institut() de Salud Carlos III (Red INMA G03/176), Generalitat de Catalunya-CIRIT 1999SGR 00241, and EU Commission (261357; 211250; 268479). Piccolipiu: The study was approved and initially funded by the Italian National Centre for Disease Prevention and Control (CCM grant 2010) and by the Italian Ministry of Health (art 12 and 12bis Dl.gs.vo 502/92). The methylation assays were funded by the European Community's Seventh Framework Programme FP7/2007-2013 project EXPOsOMICS (grant no. 308610). Z.H. is supported by the Exposomics EC FP7 grant (Grant agreement no: 308610). Z.H. and A.G. and the Epigenetics Group at IARC are supported by grants from the Institut National du Cancer (INCa, Plan Cancer-EVA-INSERM, France) and Association pour la Recherche sur le Cancer (ARC, France). Rhea: The methylation assays were funded by the European Community's Seventh Framework Programme FP7/2007-2013 project EXPOsOMICS (grant no. 308610). Z.H. is supported by the Exposomics EC FP7 grant (grant agreement no. 308610). ZH and A.G. and the Epigenetics Group at IARC are supported by grants from the Institut National du Cancer (INCa, Plan Cancer-EVA INSERM, France) and Association pour la Recherche sur le Cancer (ARC, France). PRISM: R.J.W. received funding for the PRISM cohort under HL095606 and R01 HL1143396. A.C.J. is supported by R00 ES023450. Project Viva: This Project Viva study was supported by grants from the NIH (NIH R01 HL 111108, R01 NR013945, R01 HD 034568, K24 HD069408, K23 ES022242, P01ES009825, R01AI102960, P30 ES000002) and the U.S. Environmental Protection Agency (EPA) (R832416, RD834798). This publication's contents are solely the responsibility of the grantee and do not necessarily represent the official views of the U.S. Government, the U.S. Department of Health and Human Services or the NIH, or the EPA. Further, the EPA does not endorse the purchase of any commercial products or services mentioned in the publication. MeDALL: The methylation study of MeDALL cohorts was funded by MEDALL, a collaborative project supported by the European Union under the Health Cooperation Work Programme of the 7th Framework Programme (grant agreement no. 261357). The Biobank-Based Integrative Omics Studies (BIOS) Consortium is funded by BBMRI-NL, a research 'infrastructure financed by the Dutch government (NWO 184.021.007). BAMSE: We would like to thank all the families for their participation in the BAMSE study. In addition, we would like to thank E. Haliner, S. Nilsson, and A. Lauber at the BAMSE secretary for invaluable support, as well as Mutation Analysis Facility (MAF) at Karolinska Institutet for genome-wide methylation analysis, and I. Delin for excellent technical assistance. The computations were performed on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project b201.4110.